A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

According to a study published in Biomaterials Advances, scientists at the University of Copenhagen have developed a patch ...

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon ...

Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other inflammatory skin diseases.

Ms. Reid has preexisting psoriasis, an autoimmune disease that can cause itchy ... says BioLab and KIK failed “to properly secure and manage hazardous materials stored on-site, and to properly install ...